Cargando…
Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder with unknown etiology and with different complications. The aim of this study was to evaluate the effect of omega-3 supplementation on PCOS symptoms and metabolic syndrome. MATERIALS AND METHODS: This double-bl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461594/ https://www.ncbi.nlm.nih.gov/pubmed/28616051 http://dx.doi.org/10.4103/jrms.JRMS_644_16 |
_version_ | 1783242364658122752 |
---|---|
author | Khani, Behnaz Mardanian, Farahnaz Fesharaki, Sajadeh Jafari |
author_facet | Khani, Behnaz Mardanian, Farahnaz Fesharaki, Sajadeh Jafari |
author_sort | Khani, Behnaz |
collection | PubMed |
description | BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder with unknown etiology and with different complications. The aim of this study was to evaluate the effect of omega-3 supplementation on PCOS symptoms and metabolic syndrome. MATERIALS AND METHODS: This double-blind clinical trial was performed in 2015 in Alzahra and Shahid Beheshti Hospitals, Isfahan, Iran, on 88 patients with PCOS. Intervention group took omega-3 supplements with dose of 2 g/day for 6 months (two capsules), but control group received two olive oil capsules. Finally, ultrasound and laboratory findings and the recovery rate of menstrual disorders in both groups were compared. RESULTS: After 6 months’ intervention, waist circumference (WC) was significantly lower in omega-3 as compared to control (81.18 ± 2.87 vs. 84.22 ± 2.61 cm, respectively, P < 0.0001). High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001). The interval between periods in omega-3 was significantly shorter than control (29.83 ± 4.68 vs. 47.11 ± 8.72 days, respectively, P < 0.001). CONCLUSION: Omega-3 decrease lipid profiles, WC, and interval between periods while weight, hip circumference, fasting blood sugar, number of ovarian follicle, size of ovary, bleeding volume, menstrual bleeding, and hirsutism score did not change by administration of omega-3. |
format | Online Article Text |
id | pubmed-5461594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-54615942017-06-14 Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome Khani, Behnaz Mardanian, Farahnaz Fesharaki, Sajadeh Jafari J Res Med Sci Original Article BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder with unknown etiology and with different complications. The aim of this study was to evaluate the effect of omega-3 supplementation on PCOS symptoms and metabolic syndrome. MATERIALS AND METHODS: This double-blind clinical trial was performed in 2015 in Alzahra and Shahid Beheshti Hospitals, Isfahan, Iran, on 88 patients with PCOS. Intervention group took omega-3 supplements with dose of 2 g/day for 6 months (two capsules), but control group received two olive oil capsules. Finally, ultrasound and laboratory findings and the recovery rate of menstrual disorders in both groups were compared. RESULTS: After 6 months’ intervention, waist circumference (WC) was significantly lower in omega-3 as compared to control (81.18 ± 2.87 vs. 84.22 ± 2.61 cm, respectively, P < 0.0001). High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001). The interval between periods in omega-3 was significantly shorter than control (29.83 ± 4.68 vs. 47.11 ± 8.72 days, respectively, P < 0.001). CONCLUSION: Omega-3 decrease lipid profiles, WC, and interval between periods while weight, hip circumference, fasting blood sugar, number of ovarian follicle, size of ovary, bleeding volume, menstrual bleeding, and hirsutism score did not change by administration of omega-3. Medknow Publications & Media Pvt Ltd 2017-05-30 /pmc/articles/PMC5461594/ /pubmed/28616051 http://dx.doi.org/10.4103/jrms.JRMS_644_16 Text en Copyright: © 2017 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Khani, Behnaz Mardanian, Farahnaz Fesharaki, Sajadeh Jafari Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome |
title | Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome |
title_full | Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome |
title_fullStr | Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome |
title_full_unstemmed | Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome |
title_short | Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome |
title_sort | omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461594/ https://www.ncbi.nlm.nih.gov/pubmed/28616051 http://dx.doi.org/10.4103/jrms.JRMS_644_16 |
work_keys_str_mv | AT khanibehnaz omega3supplementationeffectsonpolycysticovarysyndromesymptomsandmetabolicsyndrome AT mardanianfarahnaz omega3supplementationeffectsonpolycysticovarysyndromesymptomsandmetabolicsyndrome AT fesharakisajadehjafari omega3supplementationeffectsonpolycysticovarysyndromesymptomsandmetabolicsyndrome |